Skip to content

Denali Therapeutics

US · DNLI #2454 by market cap Listed 2017
18.45 +0.25 +1.37%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 3.24 In line with history 57th percentile
5-year average 3.22 · #319 of 514 in Biotechnology
P/E ratio -10.90 In line with history 38th percentile
5-year average -6.21 · forward -6.71
P/S ratio 140.48 In line with history 54th percentile
5-year average 986.71 · forward 18.24 · #304 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Denali Therapeutics (DNLI) 2.96B -10.73 3.19 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value23.21 Economic moatNone UncertaintyVery High

Trading 25.8% below Morningstar's fair value estimate.

Fair value

Denali Therapeutics Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 19% discount to our quantitative fair value estimate of $23.21 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its price to cash ratio of 6.2, which lies in the bottom 50% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.

Conversely, the firm's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, ranks in the top 30% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.

Denali Therapeutics discussion 0 comments

Add a comment